^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Case report: BRAF-MAD1L1 and BRAF-ZC3H7A: novel gene fusion in Rhabdomyosarcoma and Lung adenocarcinoma

Excerpt:
First-generation sequencing (Sanger) conrmed the BRAF-ZC3H7A gene fusion in the LADC patient (Figure.5). In March 2017, CT scans showed rapid disease progression and the patient died with failing to use sorafenib, which was recommended as the second-line therapy.
DOI:
10.21203/rs.3.rs-58002/v1